NCT07537881 2026-04-17
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
13 trialsNCT05849662 2026-04-15
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Recruiting
NCT05038592 2026-04-14
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT07326488 2026-04-13
A Study of MHB009C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT07509684 2026-04-13
A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07192107 2026-04-09
A Study of MHB042C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT07192120 2026-04-09
A Study of MHB048C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT07514975 2026-04-09
First-In-Human Study of KHN922 for Injection
Chengdu Kanghong Biotech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04049539 2026-04-08
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06431490 2026-04-08
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT04908111 2026-04-06
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Phase 1/2 Suspended
NCT07512583 2026-04-06
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed